Cargando…

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease

A pharmacodynamic model is presented to describe the motor effects (tapping rate, Unified Parkinson’s Disease Rating Scale [UPDRS] Part III, and investigator-rating of ON/OFF, including dyskinesia) of levodopa (LD) in patients with advanced idiopathic Parkinson’s disease (PD) treated with immediate-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Zhongping, Hsu, Ann, Gupta, Suneel, Modi, Nishit B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798100/ https://www.ncbi.nlm.nih.gov/pubmed/23426902 http://dx.doi.org/10.1002/jcph.63

Ejemplares similares

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
por: Mao, Zhongping Lily, et al.
Publicado: (2016)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
por: Morgan, John C., et al.
Publicado: (2018)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2018)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial
por: Waters, Cheryl H., et al.
Publicado: (2015)

Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials
por: Nausieda, Paul A., et al.
Publicado: (2015)

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2020)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy
por: Espay, Alberto J., et al.
Publicado: (2017)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
por: Hauser, Robert A., et al.
Publicado: (2021)

Xanthonychia Due to Staining From Carbidopa-Levodopa
por: Hwang, Jonathan Kyle, et al.
Publicado: (2023)

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study
por: Stocchi, Fabrizio, et al.
Publicado: (2015)

Improvement of Primary Writing Tremor in Parkinson’s Disease with Carbidopa/Levodopa
por: Battista, James P., et al.
Publicado: (2015)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman, Daniel Y, et al.
Publicado: (2018)

Membranous nephropathy associated with the use of levodopa-carbidopa combination
por: Chaitanya, V., et al.
Publicado: (2015)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
por: Vijiaratnam, Nirosen, et al.
Publicado: (2017)

Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens
por: Thomson, Kate, et al.
Publicado: (2021)

Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation
por: Rosebraugh, Matthew, et al.
Publicado: (2019)

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
por: Imbeah, Emelia Priscilla, et al.
Publicado: (2022)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers
por: Yao, Hsuan-Ming, et al.
Publicado: (2016)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Eruptive melanocytic nevi in a patient with Parkinson disease treated by carbidopa-levodopa
por: Haraszti, Samantha, et al.
Publicado: (2018)

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
por: Udd, Marianne, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vkgd6rgaukjuf9v9ptrbpqtsee